IR-News

AUSSENDER



4SC AG
Ansprechpartner: 4SC AG
Tel.: +49 89 700763-0
E-Mail: ir-pr@4sc.com
pta20210331037
Business news for the stock market

4SC AG: 4SC & Immunic Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838


New York and Planegg-Martinsried, Germany (pta037/31.03.2021/14:50) - 4SC AG (FSE Prime Standard: VSC), and Immunic, Inc. (Nasdaq: IMUX),   a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the signing of an agreement under which Immunic will settle its remaining obligation of a 4.4% royalty on net sales of selective oral DHODH inhibitor, IMU-838, for $17.25 million. The transaction will be payable 50% in cash and 50% in shares of Immunic’s common stock.

Immunic acquired lead program IMU-838 in September 2016 from 4SC AG through an asset acquisition, in exchange for a one-time upfront cash payment, future milestone payments and a royalty on net sales for a certain period. With completion of this transaction, no further payment obligations remain between 4SC and Immunic.

 

Jason Loveridge, Ph.D., Chief Executive Officer of 4SC, added, "4SC is very pleased to conclude this transaction as it provides non-dilutive financing for our own oncology programs, extending our cash reach well into the second half of 2022. We are expecting exciting data from some key domatinostat programs, such as DONIMI in the neoadjuvant space, in 2021 and this transaction will help us move this and other key studies in Merkel cell carcinoma forward."

 

"Execution of this agreement with 4SC is key, as it provides us with 100% of the future sales potential of our lead asset, IMU-838," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. "Backed by exceptionally strong data generated by our phase 2 EMPhASIS trial in relapsing-remitting multiple sclerosis (RRMS), we are now planning to initiate a phase 3 trial during the second half of this year. We are excited to move our pipeline forward and the acquisition of the royalties will enable us to realize the full market potential of IMU-838, not only as a treatment for RRMS but also as a potential new therapeutic option for ulcerative colitis, Crohn’s disease, COVID-19, and primary sclerosing cholangitis, thereby driving significant future value for our shareholders."

 

- Press release ends -

 

Further information

About 4SC

https://www.4sc.com/ is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. 4SC’s pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development:  http://www.4sc.com/product-pipeline/resminostat/  and  http://www.4sc.com/product-pipeline/4sc-202/.

4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself.

4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 48 employees as of 31 December 2020 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A14KL72).

 

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn’s disease, COVID-19, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. For further information, please visit:  http://www.imux.com.

 

Forward-looking information

Information set forth in this press release contains forward-looking statements, which involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond 4SC’s control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

 

Contact Information

4SC AG

+49 89 700763 0

mailto:ir-pr@4sc.com


Immunic, Inc.
Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09
mailto:jessica.breu@imux.com

 

Immunic, Inc. US IR Contact

Rx Communications Group

Paula Schwartz

+1 917 322 2216

mailto:immunic@rxir.com

 

Immunic, Inc. US Media Contact

KOGS Communication

Edna Kaplan

+1 781 639 1910

mailto:kaplan@kogspr.com

(end)
emitter: 4SC AG
Fraunhoferstr. 22
82152 Planegg-Martinsried
Germany
contact person: 4SC AG
phone: +49 89 700763-0
e-mail: ir-pr@4sc.com
website: www.4sc.de
stock exchanges: regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
ISIN(s): DE0005753818 (share)
|
|
98.140 Abonnenten
|
188.826 Meldungen
|
77.344 Pressefotos

BUSINESS

14.04.2021 - 13:59 | pressetext.redaktion
14.04.2021 - 10:00 | IfM - Institut für Management G.m.b.H
14.04.2021 - 06:10 | pressetext.redaktion
13.04.2021 - 13:30 | pressetext.redaktion
13.04.2021 - 12:20 | IG Windkraft
Top